HYOF) rose 9% after the neuro-imaging specialist confirmed its involvement in the first FDA-approved blood test for Alzheimer's disease diagnosis. The UK-listed company provided imaging analysis for Fujirebio Diagnostics' Lumipulse test, which received US regulatory clearance in May. 